Key Insights

Highlights

Treatment Research

2 treatments under study, led by Rituximab

Research Leaders

6 sponsors active, led by Northwestern University

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 90/100

Termination Rate

50.0%

2 terminated out of 4 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 3 (1)

Trial Status

Terminated2
Recruiting1
Unknown1

Clinical Trials (4)

Showing 4 of 4 trials
NCT01644903Recruiting

Proteogenomic Monitoring and Assessment of Liver Transplant Recipients

NCT05411926Unknown

Effect of PD-1 /PD-L1 Inhibitor Therapy Before Liver Transplantation on Acute Rejection After Liver Transplantation in Patients With Hepatocellular Carcinoma

NCT01117662Phase 3TerminatedPrimary

Efficacy of Rituximab in Acute Cellular Rejection in Renal Transplant Patients

NCT00579592Not ApplicableTerminatedPrimary

Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation

Showing all 4 trials

Research Network

Common Treatments

  • Rituximab1
  • Campath1h Rituximab Myfortic1

Active Sponsors

  • Northwestern University1
  • The Scripps Research Institute1
  • University of Wisconsin, Madison1
  • German Federal Ministry of Education and Research1
  • Hannover Medical School1

Top Investigators

Related Conditions

  • Hepatocellular Carcinoma1
  • Hepatitis C1
  • Chronic Kidney Disease1
  • Liver Transplant1
  • Renal Transplantation1

Activity Timeline